Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection
Upper Respiratory Tract Infection, Bacterial Infection, Chinese Medicine
About this trial
This is an interventional treatment trial for Upper Respiratory Tract Infection
Eligibility Criteria
Inclusion Criteria:
- Diagnosis with the acute upper respiratory tract infection;
- Diagnosis with wind-heat Zheng according to Chinese medicine;
- Age: 5-14 years old;
- Body temperature ≥ 37.5 ℃;
- White blood cell count> 12 × 10^9 / L, and / or neutrophil ratio over than 70%;
- The informed consent process complies with the regulations, and the legal agent or the child (≥8 years old) jointly sign the informed consent
Exclusion Criteria:
(1) Acute bacterial otitis media; (2) Patients with periodontitis or periodontal abscess (3) Candidiasis; (4) Patients with positive mycoplasma; (5) Taking antibiotics, anti-inflammatory drugs, and antihistamines; (6) Patients with severe comorbidities of heart, liver and kidney; (7) Other patients with acute infectious diseases and mycoplasma pneumoniae infections with symptoms similar to upper respiratory tract infection; (8) Children with a history of epilepsy or convulsions; (9) Patients with mental illness; (10) Those who are allergic to treatment drugs; (11) Participated in other clinical trials in the past month; (12) The investigator evaluates that it is not suitable to participate in this clinical trial or according to the investigator's judgment, who is likely to loss to follow-up.
-
Sites / Locations
- Dongfang HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
QingFei Granule+Cefuroxime group
Cefuroxime group
Cefuroxime:30mg/kg/d,bid QingFei Granule: tid
Cefuroxime:30mg/kg/d,bid